Amandeep Gakhal | Director, Protein Engineering
Sutro Biopharma

Festival of Biologics Day 1 @ 17:30

Discovery of STRO-003, a novel ROR1 targeting ADC using cell free protein synthesis and site-specific conjugation technologies

Sutro's proprietary and integrated cell-free protein synthesis platform and site-specific conjugation platform enables homogeneous ADCs with best-in-class potential. STRO-003 is a ROR1 targeting ADC with a stable β-glucoronidase cleavable linker and TOPO-1 inhibiting exatecan warhead, precisely positioned by non-natural amino acids to enable a drug-antibody ratio of 8. STRO-003 demonstrates potent and ROR1 dependent tumor killing in preclinical models with favorable safety, providing opportunity for treatment of tumors.

Amandeep Gakhal, Director, Protein Engineering, Sutro Biopharma

×

Amandeep Gakhal / Discovery of STRO-003, a novel ROR1 targeting ADC using cell free protein synthesis and site-specific conjugation technologies

Amandeep Gakhal, Director, Protein Engineering,
Sutro Biopharma

Amandeep leads the Protein Engineering group at Sutro Biopharma.  Her team discovers and engineers proteins to support Sutro’s goal of helping patients by delivering next-generation oncology therapeutics, ranging from antibody drug conjugates to cytokine derivatives.  Amandeep has over 15 years...

CloseMore